According to a new study, 50% of men in the U.S. with BRCA1/2 and metastatic castration-resistant prostate cancer receive PARP inhibitor treatment. This study also found that PARP inhibitor treatment differed by insurance coverage, with PARP inhibitors among commercially insured LESS LIKELY than those covered by government-issued insurance.
Learn more at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2839543#xd_co_f=MTdiMGE0YjctNzA5ZC00YTFiLTkzMmQtNzBkZDIzZDg0NzEz~
Reference: Ostrowski et al. JAMA Netw Open. 2025;8(10):e2534968. PMID: 41037269.